Lizeth G Meza Guzman, Craig D Hyland, Grace M Bidgood, Evelyn Leong, Zihan Shen, Wilford Goh, Jai Rautela, James E Vince, Sandra E Nicholson, Nicholas D Huntington
The clinical development of Natural Killer (NK) cell-mediated immunotherapy marks a milestone in the development of new cancer therapies and has gained traction due to the intrinsic ability of the NK cell to target and kill tumor cells. To fully harness the tumor killing ability of NK cells, we need to improve NK cell persistence and to overcome suppression of NK cell activation in the tumor microenvironment. The trans-membrane, protein tyrosine phosphatase CD45, regulates NK cell homeostasis, with the genetic loss of CD45 in mice resulting in increased numbers of mature NK cells. This suggests that CD45-deficient NK cells might display enhanced persistence following adoptive transfer. However, we demonstrate here that adoptive transfer of CD45-deficiency did not enhance NK cell persistence in mice, and instead, the homeostatic disturbance of NK cells in CD45-deficient mice stemmed from a developmental defect in the progenitor population. The enhanced maturation within the CD45-deficient NK cell compartment was intrinsic to the NK cell lineage, and independent of the developmental defect. CD45 is not a conventional immune checkpoint candidate, as systemic loss is detrimental to T and B cell development, compromising the adaptive immune system. Nonetheless, this study suggests that inhibition of CD45 in progenitor or stem cell populations may improve the yield of in vitro generated NK cells for adoptive therapy.
{"title":"CD45 limits early Natural Killer cell development","authors":"Lizeth G Meza Guzman, Craig D Hyland, Grace M Bidgood, Evelyn Leong, Zihan Shen, Wilford Goh, Jai Rautela, James E Vince, Sandra E Nicholson, Nicholas D Huntington","doi":"10.1111/imcb.12701","DOIUrl":"10.1111/imcb.12701","url":null,"abstract":"<p>The clinical development of Natural Killer (NK) cell-mediated immunotherapy marks a milestone in the development of new cancer therapies and has gained traction due to the intrinsic ability of the NK cell to target and kill tumor cells. To fully harness the tumor killing ability of NK cells, we need to improve NK cell persistence and to overcome suppression of NK cell activation in the tumor microenvironment. The trans-membrane, protein tyrosine phosphatase CD45, regulates NK cell homeostasis, with the genetic loss of CD45 in mice resulting in increased numbers of mature NK cells. This suggests that CD45-deficient NK cells might display enhanced persistence following adoptive transfer. However, we demonstrate here that adoptive transfer of CD45-deficiency did not enhance NK cell persistence in mice, and instead, the homeostatic disturbance of NK cells in CD45-deficient mice stemmed from a developmental defect in the progenitor population. The enhanced maturation within the CD45-deficient NK cell compartment was intrinsic to the NK cell lineage, and independent of the developmental defect. CD45 is not a conventional immune checkpoint candidate, as systemic loss is detrimental to T and B cell development, compromising the adaptive immune system. Nonetheless, this study suggests that inhibition of CD45 in progenitor or stem cell populations may improve the yield of <i>in vitro</i> generated NK cells for adoptive therapy.</p>","PeriodicalId":179,"journal":{"name":"Immunology & Cell Biology","volume":"102 1","pages":"58-70"},"PeriodicalIF":4.0,"publicationDate":"2023-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imcb.12701","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49672077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Over time I have recognized the value of my unique journey through science, from academia to industry, and I encourage others to appreciate how their own unique experiences shape the scientists we become. This article describes this journey.
{"title":"From academia to industry: forging a scientific career path that is uniquely you","authors":"Lauren M Webb","doi":"10.1111/imcb.12702","DOIUrl":"10.1111/imcb.12702","url":null,"abstract":"<p>Over time I have recognized the value of my unique journey through science, from academia to industry, and I encourage others to appreciate how their own unique experiences shape the scientists we become. This article describes this journey.</p>","PeriodicalId":179,"journal":{"name":"Immunology & Cell Biology","volume":"102 3","pages":"164-166"},"PeriodicalIF":4.0,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imcb.12702","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49672078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In July 1999, I took my final curtsey as an aspiring ballet dancer in London. At the time, I was devastated, having been “assessed out” by the ballet school I’d attended the year after I finished high school in Ireland. I wish I knew then what I know now: there are no endings in a career, just different paths. It took a few more iterations for me to learn that lesson. I hope my experience described in this article can provide some reassurance for anyone out there grappling with their next career move.
{"title":"From academia to industry: how reinvention and understanding your motivations can help you find your path","authors":"Louise M D’Cruz","doi":"10.1111/imcb.12703","DOIUrl":"10.1111/imcb.12703","url":null,"abstract":"<p>In July 1999, I took my final curtsey as an aspiring ballet dancer in London. At the time, I was devastated, having been “assessed out” by the ballet school I’d attended the year after I finished high school in Ireland. I wish I knew then what I know now: there are no endings in a career, just different paths. It took a few more iterations for me to learn that lesson. I hope my experience described in this article can provide some reassurance for anyone out there grappling with their next career move.</p>","PeriodicalId":179,"journal":{"name":"Immunology & Cell Biology","volume":"102 3","pages":"160-163"},"PeriodicalIF":4.0,"publicationDate":"2023-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imcb.12703","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41230933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Adrian Liston, Anne C La Flamme, Gabrielle T Belz, Christopher R Parish, Judith M Greer
This year marks the 100th year of the publication of Immunology & Cell Biology since it was first published in March 1924 as the Australian Journal of Experimental Biology and Medical Science. In this Editorial, we recount the journal from its founding, to its focus on immunology, through to the modern era.